SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-082283
Filing Date
2023-03-28
Accepted
2023-03-28 16:52:59
Documents
15
Period of Report
2023-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d470942d8k.htm   iXBRL 8-K 24893
2 EX-99.1 d470942dex991.htm EX-99.1 60167
6 GRAPHIC g470942g29x22.jpg GRAPHIC 1398
7 GRAPHIC g470942g70t18.jpg GRAPHIC 4985
  Complete submission text file 0001193125-23-082283.txt   230639

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stsa-20230328.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20230328_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20230328_pre.xml EX-101.PRE 11712
9 EXTRACTED XBRL INSTANCE DOCUMENT d470942d8k_htm.xml XML 3465
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 23770291
SIC: 2834 Pharmaceutical Preparations